Fulcrum Therapeutics Inc. (NASDAQ: FULC) reported Q2 EPS of ($0.83), $0.17 worse than the analyst estimate of ($0.66). Revenue for the quarter came in at $1.88 million versus the consensus estimate of $2.96 million.

For earnings history and earnings-related data on Fulcrum Therapeutics Inc. (FULC) click here.